StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.68+0.16 (+0.23%)

Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –

Royalty Pharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Royalty Pharma's price to sales ratio was 15.4× on Nov 11, 2026, against 9.7× a year earlier. Over the last 5 years it ranged from 6.4× to 15.4×, with a median of 8.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202615.4×+6.0
2025Dec 31, 20259.4×+2.7
2024Dec 31, 20246.7×−0.1
2023Dec 29, 20236.8×−3.1
2022Dec 30, 20229.9×+0.2
2021Dec 31, 20219.7×–

More Royalty Pharma figures

See a number that looks wrong?